Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals
American Journal of Translational Research · 2026 · 18 (7) · 5974-5987
DOI: 10.62347/cfkg8762 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Tao Tian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Beijing Friendship Hospital, Capital Medical University Beijing 100050, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Beijing Friendship Hospital, Capital Medical University Beijing 100050, China.
- Department of Interventional and Vascular Surgery, Jincheng People's Hospital Jincheng 048026, Shanxi, China.
Zitieren
APA
Tian, T., Wang, Y., & Guo, W. (2026). Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals. American Journal of Translational Research, 18(7), 5974-5987. https://doi.org/10.62347/cfkg8762
Vancouver
Tian T, Wang Y, Guo W. Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals. American Journal of Translational Research. 2026;18(7):5974-5987. doi:10.62347/cfkg8762
BibTeX
@article{Tian2026,
author = {Tian, Tao and Wang, Yang and Guo, Wei},
title = {Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {7},
pages = {5974--5987},
doi = {10.62347/cfkg8762}
}
EUVIMED